Information sur le laboratoire
Talat Bessissow (M.D./M.Sc.)
ChercheurUnité de recherche clinique
Département de médecine (McGill)
Profil de recherche
Mots-clés
Maladie de Crohn • colite ulcéreuse • cicatrisation des muqueuses • néoplasme • pathogenèseIntérêts de recherche
Ma recherche porte sur le rôle de la cicatrisation des muqueuses dans le traitement de la maladie inflammatoire chronique de l'intestin. Je m'intéresse également à l'identification des facteurs qui prédisent la rechute de la maladie.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Shehab, M., Al-Hindawi, A. & Bessissow, T. (2025). Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease-Is Dye-Based Chromoendoscopy Always the Final Answer? Authors' Reply. Alimentary pharmacology & therapeutics.
- Qatomah, A., Bessissow, A., Chen, Y.-I., Bessissow, T. & Benmassaoud, A. (2025). Management of Refractory Esophageal Variceal Bleeding when TIPSS Is Not Possible: Review of a Challenging Case. Case reports in gastroenterology, vol. 19, p. 67-71.
- Ngew, E., Kollipara, R., Bessissow, T., Karboune, S. & George, S. (2025). Nanoencapsulation enhanced the performance of β-carotene for ameliorating inflammation in patient-derived organoids. Nanomedicine (London, England), p. 1-13.
- Candel, I., Wetwittayakhlang, P., Bessissow, T. & Lakatos, P. L. (2025). The Importance of Post-Inflammatory Polyps (PIPs) in Colorectal Cancer Surveillance in Inflammatory Bowel Diseases. Journal of clinical medicine, vol. 14.
- Shehab, M., Al-Hindawi, A., Alrashed, F., Murthy, S., Bisschops, R., Hoentjen, F., Barkun, A., Singh, S. & Bessissow, T. (2025). Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease. Alimentary pharmacology & therapeutics, vol. 61, p. 938-949.
- Farkas, B., Bessissow, T., Limdi, J. K., Sethi-Arora, K., Kagramanova, A., Knyazev, O., Bezzio, C., Armuzzi, A., Lukas, M., Michalopoulos, G., Chaskova, E., Savarino, E. V., Castiglione, F., Rispo, A., Schäfer, E., Saibeni, S., Filip, R., Attauabi, M., Fousekis, F. S., Bacsur, P., Resál, T., Bálint, A., Ivány, E., Szepes, Z., Bősze, Z., Fábián, A., Bor, R., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study. Journal of clinical medicine, vol. 13.
- Solitano, V., Narula, N., Ma, C., Nanayakkara, A., Suarez, K. E., Zoughlami, A., Guizzetti, L., Bessissow, T. & Jairath, V. (2024). Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study. The American journal of gastroenterology.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
Voir aussi
